IDO1 and neoplasm: While previous publications on IDO inhibition trials have highlighted various limitations such as the adequacy of IDO1 inhibition within the tumor, proper dosage, and drug exposure, one of our findings that began to address the lack of efficacy of IDO inhibition was our demonstration of the compensatory role of TDO2 in overcoming the blockade of IDO1 [79].